Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07876518). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Overweight and/or Obesity. Interventions: DRUG: Placebo; DRUG: PF-08656795. Primary outcome measures: Incidence of Treatment Emergent Adverse Events (TEAEs) , Up to 12 weeks after last dose. Brief summary: This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity. Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study. The study is seeking participants who are: * adults, 18 to 70 years of age (inclusive) * have a body mass index (BMI) equal to, or more than 25 kilograms/meter square (kg/m2) up to 40 kg/m2. * limited mild, stable long-term medical conditions are allowed as assessed by the study doctor. People who want to join the study will first go through a screening period of up to 4 weeks. The study will look at how the study medicine is tolerated, including whether participants have any reactions. It will assess how they feel after receiving multiple doses. It will also measure the amounts of study medicine in the blood and urine over time. Participants will take part in this study for about 24 to 40 weeks including treatment and follow-up period after the final dose. Treatment duration may vary depending on their assigned group.